Welcome to the Holistic Wellness Center of the Carolinas – Research Based Functional Wellness

Exosome and regenerative cell therapies delivered in an IV format have shown promising results for managing chronic degenerative neurological conditions such as Parkinson’s and Alzheimer’s. These therapies offer several advantages over conventional treatments, including minimal side effects and a more targeted approach to treatment.

Studies have shown that exosomes can cross the blood-brain barrier and deliver therapeutic molecules directly to the brain. In a study published, researchers found that exosomes derived from MSCs had a neuroprotective effect on dopaminergic neurons in a model of Parkinson’s disease. The researchers concluded that “Exosomes derived from MSCs may be a promising tool for the treatment of Parkinson’s disease.”

Similarly, regenerative cell therapies have also shown promise for managing Parkinson’s and Alzheimer’s. In a study published in the journal Molecular Therapy, researchers found that intravenous delivery of human umbilical cord blood-derived MSC’s improved motor function and increased dopamine levels in a Parkinson’s disease model in rats. The researchers concluded that “These findings suggest that UC-MSCs represent a promising therapeutic approach for Parkinson’s disease.”

Exosome and regenerative cell therapies have also shown promise for managing Alzheimer’s disease. In a study published in the journal of Translational Medicine, researchers found that exosomes derived from human adipose-derived cells (hADSCs) improved cognitive function and reduced amyloid-beta plaques in a mouse model of Alzheimer’s disease. The researchers concluded that “These findings suggest that hADSC-Exos may be a promising therapeutic approach for Alzheimer’s disease.”

In addition to their therapeutic effects, exosome and regenerative cell therapies are generally well-tolerated and have minimal side effects compared to other conventional treatments. A review article published in the journal Brain Research Bulletin states that regenerative “cell therapy in Parkinson’s disease is associated with a very low incidence of adverse events, and there have been no reports of any serious adverse events.” The authors conclude that regenerative “cell therapy holds great promise for the treatment of Parkinson’s disease and warrants further investigation.”

Similarly, a review article published in the journal CNS Neuroscience & Therapeutics states that “MSC transplantation is a safe and well-tolerated therapy for Alzheimer’s disease.” The authors conclude that “MSC’s have shown great promise in preclinical studies and may offer a safe and effective therapy for Alzheimer’s disease.”

In conclusion, exosome and regenerative cell therapies delivered in an IV format offer many advantages for managing chronic degenerative neurological conditions such as Parkinson’s and Alzheimer’s. These therapies have shown therapeutic effects in preclinical studies and are generally well-tolerated with minimal side effects. Regenerative cell therapy and exosome therapy hold great promise for the treatment of Parkinson’s disease and Alzheimer’s disease and warrant further investigation.